By a News Reporter-Staff News Editor at Cancer Weekly -- Data detailed on Molecular Imaging have been presented. According to news reporting originating in Cambridge, United Kingdom, by NewsRx journalists, research stated, "Deregulation of c-Myc plays a central role in the tumorigenesis of many human cancers. Yet, the development of drugs regulating c-Myc activity has been challenging."
The news reporters obtained a quote from the research from the University of Cambridge, "To facilitate the identification of c-Myc inhibitors, we developed a molecular imaging sensor-based high-throughput screening (HTS) system. This system uses a cell-based assay to detect c-Myc activation in aHTSformat, which is established from a pure clone of a stable breast cancer cell line that constitutively expresses a c-Myc activation sensor. Optimization of the assay performance in the HTS format resulted in uniform and robust signals at the baseline. Using this system, we conducted a quantitative HTS against approximately 5,000 existing bioactive compounds from five different libraries. Thirty-nine potential hits were identified, including currently known c-Myc inhibitors. There are a few among the top potent hits that are not known for anti-c-Myc activity. One of these hits is nitazoxanide, a thiazolide for treating human protozoal infections. Validation of nitazoxanide in different cancer cell lines revealed a high potency for c-Myc inhibition with IC50 ranging between 10 and 500 nmol/L. Oral administration of nitazoxanide in breast cancer xenograft mouse models significantly suppressed tumor growth by inhibition of c-Myc and induction of apoptosis. These findings suggest a potential of nitazoxanide to be repurposed as a new antitumor agent for inhibition of c-Myc-associated neoplasia."
According to the news reporters, the research concluded: "Our work also demonstrated the unique advantage of molecular imaging in accelerating discovery of drugs for c-Myctargeted cancer therapy."
For more information on this research see: A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide. Molecular Cancer Therapeutics, 2013;12(9):1896-1905. Molecular Cancer Therapeutics can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research - www.aacr.com; Molecular Cancer Therapeutics - mct.aacrjournals.org/)
Our news correspondents report that additional information may be obtained by contacting H. Fan-Minogue, University of Cambridge, Dept. of Radiol, Sch Clin Med, Cambridge, United Kingdom. Additional authors for this research include S. Bodapati, D. Solow-Cordero, A. Fan, R. Paulmurugan, T.F. Massoud, D.W. Felsher and S.S. Gambhir (see also Molecular Imaging).
Keywords for this news article include: Europe, Cancer, Oncology, Cambridge, United Kingdom, Nanotechnology, Molecular Imaging, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC